Abstract:Defective mitophagy is consistently found in postmortem brain and iPSC-derived neurons from Alzheimer disease (AD) patients. However, there is a lack of extensive examination of mitophagy status in serum or cerebrospinal fluid (CSF), and the clinical potential of mitophagy biomarkers has not been tested. We quantified biomarkers of mitophagy/autophagy and lysosomal degradation (PINK1, BNIP3L and TFEB) in CSF and serum from 246 individuals, covering mild cognitive impairment due to AD (MCI-AD, n = 100), dementia due to AD (AD-dementia, n = 100), and cognitively unimpaired individuals (CU, n = 46), recruited from the Czech Brain Aging Study. Cognitive function and brain atrophy were also assessed. Our data show that serum and CSF PINK1 and serum BNIP3L were higher, and serum TFEB was lower in individuals with AD than in corresponding CU individuals. Additionally, the magnitude of mitophagy impairment correlated with the severity of clinical indicators in AD patients. Specifically, levels of PINK1 positively correlated with phosphorylated (p)-MAPT/tau (181), total (t)-MAPT/tau, NEFL (neurofilament light chain), and NRGN (neurogranin) levels in CSF and negatively with memory, executive function, and language domain. Serum TFEB levels negatively correlated with NEFL and positively with executive function and language. This study reveals mitophagy impairment reflected in biofluid biomarkers of individuals with AD and associated with more advanced AD pathology. Abbreviation: Aβ: amyloid beta; AD: Alzheimer disease; AVs: autophagic vacuoles; BNIP3L: BCL2 interacting protein 3 like; CU: cognitively unimpaired; CSF: cerebrospinal fluid; LAMP1: lysosomal-associated membrane protein 1; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MCI: mild cognitive impairment; NRGN: neurogranin; NEFL: neurofilament light chain; p-MAPT/tau: phosphorylated microtubule associated protein tau; PINK1: PTEN induced kinase 1; t-MAPT/tau: total microtubule associated protein tau; TFEB: transcription factor EB; TMT: Trail Making Test.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: to explore the changes of autophagy - related biomarkers (especially the mitophagy markers PINK1, BNIP3L and TFEB) in cerebrospinal fluid (CSF) and serum in patients with Alzheimer's disease (AD) at different stages of the disease, and to evaluate the association of these biomarkers with AD pathological features and clinical symptoms. ### Research Background Alzheimer's disease (AD) is one of the most common neurodegenerative diseases, affecting more than 50 million people worldwide. Although there are currently some drugs such as Lecanemab and Donanemab that can slow down the memory decline in early - stage AD patients, a method to cure AD has not yet been found. Therefore, it is particularly important to deeply understand the pathogenesis of AD and find effective diagnostic, therapeutic or prognostic biomarkers. Mitophagy is a selective autophagy process for removing damaged or dysfunctional mitochondria. Studies have shown that there are mitophagy defects in the post - mortem brain tissues of AD patients and neurons derived from induced pluripotent stem cells (iPSC). However, detailed studies on the mitophagy state in serum or cerebrospinal fluid are still insufficient, and its potential as a clinical biomarker has not been tested. ### Research Objectives The main objectives of this study are: 1. **Quantify biomarkers**: Measure the mitophagy/autophagy and lysosomal degradation markers (PINK1, BNIP3L and TFEB) in the cerebrospinal fluid and serum of 246 individuals (including mild cognitive impairment with AD, AD dementia and cognitively normal individuals), and determine whether the levels of these biomarkers are related to the AD stage. 2. **Evaluate the influence of genetic factors**: Explore the influence of the major genetic risk factor APOE ε4 on the differences in these proteins. 3. **Analyze correlations**: Evaluate the relationship between mitophagy markers and AD pathological markers (such as Aβ42/40, p - MAPT/tau [181], t - MAPT/tau), neurodegenerative markers (NEFL), synaptic dysfunction markers (NRGN), cognitive status and brain atrophy. 4. **Explore the associations between markers**: Determine whether the mitophagy markers in serum and cerebrospinal fluid are correlated with each other. ### Main Findings The research results show that in AD patients, especially in the AD dementia stage, the levels of PINK1 in cerebrospinal fluid and serum and BNIP3L in serum are significantly increased, while the level of TFEB in serum is significantly decreased. These changes are related to the severity of AD pathology. Specifically, the PINK1 level is positively correlated with the levels of phosphorylated tau protein, total tau protein, neurofilament light chain (NEFL) and neurogranin (NRGN), and is negatively correlated with memory, executive function and language ability. In addition, the level of TFEB in serum is negatively correlated with NEFL, and is positively correlated with executive function and language ability. ### Conclusions This study reveals the biomarker changes in biological fluids that reflect mitophagy dysfunction in AD patients and are related to more severe AD pathological features. This provides a theoretical basis for the development of new intervention measures based on mitochondrial function, and suggests that mitophagy markers may become important biomarkers for AD progression and diagnosis. ### Formula Summary - The concentration changes of PINK1, BNIP3L and TFEB were measured by ELISA method. - Statistical analysis was carried out using ANOVA and ANCOVA methods, adjusting for factors such as age and sex. - Correlation analysis was evaluated using Pearson correlation coefficient (r - value). Hopefully, this information can help you better understand the research objectives and main findings of this paper. If you have more questions, please feel free to continue asking!

Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Identification and potential clinical applications of novel autophagy/mitophagy proteins in the biofluids of Alzheimer's disease patients

Pooled analysis of frontal lobe transcriptomic data identifies key mitophagy gene changes in Alzheimer's disease brain

Systemic and central nervous system metabolic alterations in Alzheimer’s disease

Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer’s disease and mild cognitive impairment

Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease

Mitochondrial alterations in fibroblasts from sporadic Alzheimer's disease (AD) patients correlate with AD-related clinical hallmarks

Integrated Analysis of Ultra-Deep Proteomes in Cortex, Cerebrospinal Fluid and Serum Reveals a Mitochondrial Signature in Alzheimer’s Disease

Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease

The Role of Mitophagy in the Regulation of Mitochondrial Energetic Status in Neurons

Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients

Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow

Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI)

Mitochondrial Alterations in Alzheimer's Disease: Insight from the 5xFAD Mouse Model

O-GlcNAc impacts mitophagy via the PINK1-dependent pathway

Mitochondrial Molecular Abnormalities Revealed by Proteomic Analysis of Hippocampal Organelles of Mice Triple Transgenic for Alzheimer Disease.

MICROGLIAL ACTIVATION AND TAU BURDEN PREDICT COGNITIVE DECLINE IN ALZHEIMER’S DISEASE

Effect of Alternating Nicotinamide Phosphoribosyltransferase Expression Levels on Mitophagy in Alzheimer's Disease Mouse Models

Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum

Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative